Profile data is unavailable for this security.
About the company
Ambu A/S is a Denmark-based company engaged in the development, manufacture and marketing of diagnostic and life-supporting devices for hospitals and rescue services. The Company’s operations are structured into three business areas: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. The Anaesthesia business area offers a range of products such as resuscitators, face masks and laryngeal masks. The Patient Monitoring & Diagnostics business area comprises single use electrodes for cardiological and neurological examinations. The target groups for these products are hospitals, clinics, ambulance services and sleep labs. The Emergency Care business area offers ventilation bags, neck collars and manikins for first-aid training. The Company markets its products worldwide. The Company operates King Systems Inc, First Water Heathcote Ltd and Invendo Medical GmbH as subsidiaries.
- Revenue in DKK (TTM)5.08bn
- Net income in DKK367.00m
- Incorporated1956
- Employees4.75k
- LocationAmbu A/SBaltorpbakken 13BALLERUP 2750DenmarkDNK
- Phone+45 72252000
- Fax+45 72252050
- Websitehttps://www.ambu.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arjo AB (publ) | 7.28bn | 339.87m | 6.79bn | 6.71k | 21.41 | 1.37 | 6.68 | 0.9323 | 1.90 | 1.90 | 40.76 | 29.72 | 0.6911 | 4.15 | 6.31 | 1,632,980.00 | 3.21 | 3.55 | 4.44 | 5.55 | 43.43 | 44.01 | 4.64 | 5.41 | 0.6913 | 4.14 | 0.4024 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
| Biotage AB | 1.30bn | 154.84m | 8.40bn | 669.00 | 53.18 | 3.29 | 31.78 | 6.47 | 3.01 | 3.01 | 25.57 | 48.61 | 0.5276 | 2.01 | 7.78 | 2,939,169.00 | 6.29 | 10.74 | 7.33 | 12.77 | 62.19 | 61.34 | 11.91 | 15.77 | 1.52 | 8.95 | 0.062 | 40.11 | 18.90 | 15.37 | -8.21 | 7.97 | 14.05 | 1.30 |
| Xvivo Perfusion AB | 421.85m | 65.89m | 8.43bn | 148.00 | 123.00 | 6.42 | 77.96 | 19.99 | 3.32 | 3.32 | 21.18 | 63.59 | 0.322 | 1.28 | 4.27 | 4,018,431.00 | 5.03 | 1.24 | 5.49 | 1.33 | 73.94 | 73.14 | 15.62 | 4.76 | 3.40 | -- | 0.0152 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
| Embla Medical hf | 5.58bn | 395.15m | 12.61bn | 4.00k | 31.83 | 2.48 | 16.80 | 2.26 | 0.9263 | 0.9263 | 13.07 | 11.88 | 0.5582 | 2.20 | 6.60 | 1,396,049.00 | 3.96 | 4.06 | 4.68 | 4.76 | 61.41 | 62.47 | 7.09 | 6.91 | 1.07 | 5.81 | 0.4325 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| Vitrolife AB | 2.30bn | -2.52bn | 14.85bn | 1.13k | -- | 1.71 | -- | 6.47 | -28.33 | -28.33 | 25.84 | 97.73 | 0.1859 | 3.76 | 6.54 | 3,242,818.00 | -20.38 | -4.57 | -21.03 | -4.78 | 56.39 | 58.38 | -109.60 | -21.89 | 2.98 | -30.31 | 0.1353 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Elekta AB (publ) | 11.89bn | 853.61m | 15.84bn | 4.58k | 19.29 | 2.32 | 9.89 | 1.33 | 3.40 | 3.40 | 47.32 | 28.20 | 0.5939 | 3.58 | 3.01 | -- | 4.27 | 4.19 | 7.60 | 7.51 | 37.55 | 39.03 | 7.19 | 7.37 | 0.7644 | 3.85 | 0.4021 | 71.71 | 7.41 | 5.98 | 38.07 | 1.68 | 20.06 | 5.92 |
| Sectra AB | 1.13bn | 281.07m | 28.53bn | 1.14k | 108.03 | 29.48 | 81.65 | 25.20 | 2.22 | 2.22 | 8.95 | 8.15 | 0.5801 | -- | 3.60 | 1,513,253.00 | 14.41 | 15.75 | 28.61 | 29.52 | 47.24 | 64.95 | 24.83 | 19.59 | -- | -- | 0.0199 | -- | 26.84 | 4.06 | 14.25 | 16.58 | 48.37 | -- |
| Getinge AB | 21.13bn | 1.50bn | 30.13bn | 11.86k | 21.55 | 1.52 | 10.94 | 1.43 | 8.39 | 8.39 | 118.22 | 118.80 | 0.6001 | 2.53 | 6.79 | 2,742,908.00 | 4.29 | 5.31 | 5.56 | 6.98 | 45.37 | 47.83 | 7.15 | 8.69 | 0.7569 | 8.93 | 0.2035 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| Ambu A/S | 5.08bn | 367.00m | 32.06bn | 4.75k | 98.78 | 6.48 | 43.62 | 6.32 | 1.38 | 1.38 | 19.09 | 21.05 | 0.7251 | 2.13 | 7.17 | 1,099,437.00 | 5.24 | 3.81 | 5.99 | 4.62 | 57.91 | 59.37 | 7.23 | 5.43 | 1.49 | 16.93 | 0.101 | 22.89 | 7.45 | 12.88 | 80.65 | -13.00 | 6.67 | -- |
| Demant A/S | 22.44bn | 2.55bn | 65.88bn | 21.62k | 26.06 | 7.10 | -- | 2.94 | 11.44 | 8.05 | 100.58 | 41.97 | 0.7431 | 2.05 | 5.88 | 1,037,923.00 | 8.46 | 8.27 | 12.20 | 13.23 | 73.72 | 74.14 | 11.38 | 11.34 | 0.9529 | 5.98 | 0.6075 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Schroder Investment Management Ltd.as of 31 Mar 2024 | 17.46m | 7.43% |
| Fundsmith LLPas of 31 Dec 2022 | 9.47m | 4.03% |
| Allianz Global Investors GmbHas of 30 Apr 2024 | 7.82m | 3.33% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 6.78m | 2.89% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 6.70m | 2.85% |
| Brown Capital Management LLCas of 31 Mar 2024 | 5.49m | 2.34% |
| Artisan Partners LPas of 31 Mar 2024 | 5.35m | 2.28% |
| Capital International Ltd.as of 31 Mar 2024 | 5.02m | 2.14% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 4.63m | 1.97% |
| Baillie Gifford & Co.as of 31 May 2024 | 3.78m | 1.61% |
